These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1154 related items for PubMed ID: 29730375

  • 1. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    JACC Cardiovasc Interv; 2018 May 28; 11(10):934-941. PubMed ID: 29730375
    [Abstract] [Full Text] [Related]

  • 2. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    J Endovasc Ther; 2017 Aug 28; 24(4):459-467. PubMed ID: 28558502
    [Abstract] [Full Text] [Related]

  • 3. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K.
    J Endovasc Ther; 2016 Jun 28; 23(3):409-16. PubMed ID: 27117972
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, Brechtel K, Speck U, Zeller T.
    J Endovasc Ther; 2020 Apr 28; 27(2):276-286. PubMed ID: 32096451
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1386-92. PubMed ID: 27388828
    [Abstract] [Full Text] [Related]

  • 6. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, Metzger C, Micari A, Sachar R, Jaff MR, Wang H, Hasenbank MS, Krishnan P, IN.PACT SFA Trial Investigators.
    Circ Cardiovasc Interv; 2018 Jan 11; 11(1):e005891. PubMed ID: 29326153
    [Abstract] [Full Text] [Related]

  • 7. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, Krishnan P, Scheinert D, Micari A, Wang H, Masters M, Tepe G.
    Circ Cardiovasc Interv; 2019 Jun 11; 12(6):e007702. PubMed ID: 31195825
    [Abstract] [Full Text] [Related]

  • 8. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K.
    JACC Cardiovasc Interv; 2014 Jan 11; 7(1):10-9. PubMed ID: 24456716
    [Abstract] [Full Text] [Related]

  • 9. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E, Gerardi D, Magliulo F, Zhelev D, Chervenkoff V, Taeymans K, Kotasov D, Goverde P, Giugliano G, Trimarco B, Esposito G.
    J Endovasc Ther; 2019 Feb 11; 26(1):26-30. PubMed ID: 30760132
    [Abstract] [Full Text] [Related]

  • 10. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
    Torsello G, Stavroulakis K, Brodmann M, Micari A, Tepe G, Veroux P, Benko A, Choi D, Vermassen FEG, Jaff MR, Guo J, Dobranszki R, Zeller T, IN.PACT Global Investigators.
    J Endovasc Ther; 2020 Oct 11; 27(5):693-705. PubMed ID: 32583749
    [Abstract] [Full Text] [Related]

  • 11. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
    Xu Y, Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W.
    JACC Cardiovasc Interv; 2018 Dec 10; 11(23):2347-2353. PubMed ID: 30448170
    [Abstract] [Full Text] [Related]

  • 12. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A, Vadalà G, Castriota F, Liso A, Grattoni C, Russo P, Marchese A, Pantaleo P, Roscitano G, Cesana BM, Cremonesi A.
    JACC Cardiovasc Interv; 2016 May 09; 9(9):950-6. PubMed ID: 27151609
    [Abstract] [Full Text] [Related]

  • 13. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, Ookubo H, Yokoi H, MDT-2113 SFA Japan Investigators.
    J Endovasc Ther; 2018 Feb 09; 25(1):109-117. PubMed ID: 29264999
    [Abstract] [Full Text] [Related]

  • 14. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M, Keirse K, Scheinert D, Spak L, Jaff MR, Schmahl R, Li P, Zeller T, IN.PACT Global Study Investigators.
    JACC Cardiovasc Interv; 2017 Oct 23; 10(20):2113-2123. PubMed ID: 29050631
    [Abstract] [Full Text] [Related]

  • 15. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study.
    Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S.
    Catheter Cardiovasc Interv; 2015 Aug 23; 86(2):278-86. PubMed ID: 25708850
    [Abstract] [Full Text] [Related]

  • 16. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C, Lakhlifi E, Colacchio EC, Midy D, Bérard X, Poirier M, Ducasse E.
    J Vasc Surg; 2019 Sep 23; 70(3):981-995.e10. PubMed ID: 31126769
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP.
    Circulation; 2017 Sep 19; 136(12):1102-1113. PubMed ID: 28729250
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.